Physician profile
Bobby C Brock
NPI 1881790657
$2,779.65
in general payments reported to CMS, 2019-2025
35 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2021: $76.88 · 2023: $73.96 · 2024: $387 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $423.52 | 2019 | |
| Novo Nordisk INC | $296.10 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $166.40 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Globus Medical, INC. | $147.27 | 2025 | Senza |
| Lilly USA, LLC | $142.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Aerin Medical INC. | $135.00 | 2025 | |
| Lupin INC. | $115.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $110.38 | 2024-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Madrigal Pharmaceuticals | $97.92 | 2024 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $89.97 | 2025 | |
| Exact Sciences Corporation | $89.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $89.01 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.75 | 2025 | Xifaxan, Relistor |
| Amgen INC. | $83.38 | 2019-2025 | Evenity, Prolia |
| Medtronic, INC. | $79.27 | 2021-2024 | Intellis Adaptivestim |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.96 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $64.83 | 2019-2025 | Breztri, Farxiga |
| Antares Pharma, INC. | $62.58 | 2024-2025 | Xyosted |
| Averitas Pharma INC. | $39.78 | 2025 | Qutenza |
| Sumitomo Pharma America, INC. | $36.30 | 2024-2025 | Gemtesa |
| Acclarent, INC | $34.65 | 2019 | |
| Dexcom, INC. | $33.11 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $32.17 | 2025 | Voquezna |
| Allergan, INC. | $29.35 | 2019 | |
| Akcea Therapeutics, INC. | $28.70 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.63 | 2025 | Caplyta |
| Abbvie INC. | $23.03 | 2025 | |
| Esperion Therapeutics, INC. | $21.71 | 2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $20.14 | 2024 | Keveyis |
| Abbott Laboratories | $19.93 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $17.66 | 2019 | |
| Nevro Corp. | $16.81 | 2024 | Senza |
| Janssen Pharmaceuticals, INC | $16.19 | 2019 | |
| Shield Therapeutics INC | $15.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.